Myungmoon Rosuvastatin Indications/Uses

MYUNGMOON ROSUVASTATIN is an HMG-CoA reductase inhibitor indicated for: Adult patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C and TG levels and increase HDL-C; Pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an adequate trial of diet therapy; Adult patients with hypertriglyceridemia as an adjunct to diet; Adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet; Adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB; Slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet; Risk reduction of MI, stroke and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors.